Literature DB >> 33252814

Prevalence of Hepatitis C and treatment uptake in regional Victoria.

Kristen Glenister1, William Kemp2, Dunya Tomic2, David Simmons3, Stuart Roberts2.   

Abstract

OBJECTIVE: The objective of this study was to assess the prevalence of hepatitis C virus (HCV) in regional Victoria and assess amenability to treatment.
METHODS: Households were randomly selected and one adult from each was invited to a 'clinic', which included HCV, liver function and liver stiffness/fibrosis tests. Participants reactive to HCV were asked about their amenability to treatment.
RESULTS: The study identified eight cases of HCV (antibody and PCR reactive, 1.1%) among 748 participants, half of which were new diagnoses. Most of the HCV-reactive participants were male (89%). Liver function and fibrosis were not significantly different between HCV-reactive and non-reactive participants. Most participants notified of their HCV were amenable to treatment.
CONCLUSIONS: The prevalence of HCV in this regional Victorian study (1.1%) was similar to the Australian modelled prevalence estimates. Most participants were amenable to treatment. Implications for public health: The unique opportunity to eliminate HCV requires a reorientation of the public health response toward systematic implementation of treatment to address barriers and reduce stigma and discrimination for marginalised populations. This should include targeting regional areas where the HCV prevalence of undiagnosed cases may be higher than metropolitan areas.
© 2020 The Authors.

Entities:  

Keywords:  hepatitis C; prevalence; regional; rural; treatment

Mesh:

Year:  2020        PMID: 33252814     DOI: 10.1111/1753-6405.13040

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  1 in total

Review 1.  Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region.

Authors:  Jenny Iversen; Handan Wand; Po-Lin Chan; Linh-Vi Le; Lisa Maher
Journal:  Viruses       Date:  2022-07-15       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.